|
China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) Bundle
Explore the financial future of China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,503.9 | 9,111.5 | 9,446.9 | 10,222.1 | 11,211.6 | 12,016.4 | 12,878.9 | 13,803.3 | 14,794.1 | 15,856.0 |
| Revenue Growth, % | 0 | 7.14 | 3.68 | 8.21 | 9.68 | 7.18 | 7.18 | 7.18 | 7.18 | 7.18 |
| EBITDA | 1,597.0 | 1,588.7 | 1,996.4 | 2,224.8 | 2,635.2 | 2,466.2 | 2,643.2 | 2,832.9 | 3,036.3 | 3,254.2 |
| EBITDA, % | 18.78 | 17.44 | 21.13 | 21.76 | 23.5 | 20.52 | 20.52 | 20.52 | 20.52 | 20.52 |
| Depreciation | 378.0 | 470.6 | 565.8 | 655.5 | 756.3 | 691.1 | 740.7 | 793.9 | 850.9 | 911.9 |
| Depreciation, % | 4.45 | 5.16 | 5.99 | 6.41 | 6.75 | 5.75 | 5.75 | 5.75 | 5.75 | 5.75 |
| EBIT | 1,218.9 | 1,118.1 | 1,430.6 | 1,569.4 | 1,879.0 | 1,775.1 | 1,902.5 | 2,039.1 | 2,185.4 | 2,342.3 |
| EBIT, % | 14.33 | 12.27 | 15.14 | 15.35 | 16.76 | 14.77 | 14.77 | 14.77 | 14.77 | 14.77 |
| Total Cash | 3,262.2 | 3,637.6 | 2,830.7 | 3,457.0 | 2,850.7 | 4,025.4 | 4,314.3 | 4,624.0 | 4,955.9 | 5,311.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2,086.0 | 1,978.2 | 2,631.8 | 2,403.5 | 2,781.5 | 2,942.1 | 3,153.3 | 3,379.7 | 3,622.2 | 3,882.2 |
| Account Receivables, % | 24.53 | 21.71 | 27.86 | 23.51 | 24.81 | 24.48 | 24.48 | 24.48 | 24.48 | 24.48 |
| Inventories | 1,289.3 | 1,665.5 | 1,878.6 | 1,562.4 | 1,594.1 | 1,990.6 | 2,133.5 | 2,286.6 | 2,450.8 | 2,626.7 |
| Inventories, % | 15.16 | 18.28 | 19.89 | 15.28 | 14.22 | 16.57 | 16.57 | 16.57 | 16.57 | 16.57 |
| Accounts Payable | 848.0 | 847.4 | 731.3 | 740.5 | 835.8 | 1,002.5 | 1,074.4 | 1,151.6 | 1,234.2 | 1,322.8 |
| Accounts Payable, % | 9.97 | 9.3 | 7.74 | 7.24 | 7.45 | 8.34 | 8.34 | 8.34 | 8.34 | 8.34 |
| Capital Expenditure | -348.1 | -491.7 | -525.5 | -614.3 | -637.5 | -642.8 | -689.0 | -738.4 | -791.4 | -848.2 |
| Capital Expenditure, % | -4.09 | -5.4 | -5.56 | -6.01 | -5.69 | -5.35 | -5.35 | -5.35 | -5.35 | -5.35 |
| Tax Rate, % | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 |
| EBITAT | 1,008.4 | 933.1 | 1,193.4 | 1,335.5 | 1,638.4 | 1,497.8 | 1,605.3 | 1,720.5 | 1,844.0 | 1,976.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,488.9 | 643.0 | 250.9 | 1,930.3 | 1,443.0 | 1,155.5 | 1,374.9 | 1,473.6 | 1,579.4 | 1,692.8 |
| WACC, % | 4.47 | 4.47 | 4.47 | 4.47 | 4.48 | 4.47 | 4.47 | 4.47 | 4.47 | 4.47 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 6,344.7 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 1,744 | |||||||||
| Terminal Value | 118,652 | |||||||||
| Present Terminal Value | 95,351 | |||||||||
| Enterprise Value | 101,696 | |||||||||
| Net Debt | -1,675 | |||||||||
| Equity Value | 103,371 | |||||||||
| Diluted Shares Outstanding, MM | 1,028 | |||||||||
| Equity Value Per Share | 100.58 |
Benefits You'll Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-loaded financial data for China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS).
- Actual Market Data: Access to historical performance data and projected estimates (highlighted in the yellow cells).
- Adjustable Forecast Assumptions: Modify key parameters like revenue growth, EBITDA %, and WACC to suit your analysis.
- Instant Calculations: Quickly evaluate how your input variables affect the valuation of China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS).
- Professional-Grade Tool: Designed specifically for investors, CFOs, consultants, and financial analysts.
- User-Centric Design: Organized for straightforward navigation and usability, complete with detailed step-by-step guidance.
Key Features
- Comprehensive Historical Data: Access China Resources Double-Crane Pharmaceutical Co., Ltd.’s financial statements and pre-filled forecasts.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Valuation: Watch as the intrinsic value of China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS) updates instantly.
- Intuitive Visual Outputs: Engaging dashboard charts present valuation results and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Functions
- Step 1: Download the Excel spreadsheet.
- Step 2: Examine the pre-filled financial data and projections for China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS).
- Step 3: Adjust key parameters such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Calculator for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062SS)?
- Reliable Data: Utilize genuine China Resources Double-Crane financial information for trustworthy valuation outcomes.
- Flexible Customization: Tailor essential inputs like growth forecasts, WACC, and tax rates to align with your expectations.
- Efficiency Boost: Ready-to-use calculations save you the hassle of starting from zero.
- Professional-Quality Tool: Crafted for investors, analysts, and industry specialists.
- Easy to Use: Streamlined design and clear, step-by-step guidance make it accessible for everyone.
Who Can Benefit from This Product?
- Pharmaceutical Students: Master valuation methods while utilizing real-world data.
- Researchers: Integrate advanced financial models into academic studies or publications.
- Investors: Validate your investment hypotheses by analyzing valuation outcomes for China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS).
- Financial Analysts: Enhance your efficiency with a customizable DCF model designed specifically for the pharmaceutical sector.
- Entrepreneurs: Understand the valuation processes applied to major pharmaceutical companies like China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS).
Contents of the Template
- Pre-Filled DCF Model: Financial data for China Resources Double-Crane Pharmaceutical Co., Ltd. (600062SS) preloaded for immediate application.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess China Resources Double-Crane's profitability, leverage, and operational efficiency.
- Editable Inputs: Customize assumptions such as growth rates, profit margins, and capital expenditures to align with your scenarios.
- Financial Statements: Annual and quarterly reports available for in-depth analysis.
- Interactive Dashboard: Effortlessly visualize essential valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.